Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Shadi Yaqoubi"'
Publikováno v:
Advances in Pharmacological and Pharmaceutical Sciences, Vol 2024 (2024)
Curcumin has shown beneficial effects on pulmonary diseases with chronic inflammation or abnormal inflammatory responses, including chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis. Clinical applications of curcumin are limited d
Externí odkaz:
https://doaj.org/article/9243dbdb79bb40f5a209e3e3751599dd
Publikováno v:
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, Vol 30, Iss 2, Pp 4535-4552 (2022)
Introduction: The use of pulmonary drug delivery as a non-invasive drug delivery system for the systemic treatment of diseases as well as the topical treatment of respiratory diseases is increasing. Among the various inhaled formulations, inhaled dry
Externí odkaz:
https://doaj.org/article/14d07574adde4d7284276c96e563234e
Autor:
Elahehnaz Parhizkar, Delaram Sadeghinia, Hamed Hamishehkar, Shadi Yaqoubi, Ali Nokhodchi, Shohreh Alipour
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 12, Iss 2, Pp 336-345 (2022)
Purpose: Pulmonary tuberculosis (TB) is a worldwide life-threatening infection. Therecommended anti-TB regimen contains oral administration of classical first-line drugs suchas rifampin for 6-24 months which often leads to low patient compliance due
Externí odkaz:
https://doaj.org/article/12c2d9beb0f444208ccc2024d0b1964d
Autor:
Azin Jahangiri, Ali Nokhodchi, Kofi Asare-Addo, Erfan Salehzadeh, Shahram Emami, Shadi Yaqoubi, Hamed Hamishehkar
Publikováno v:
Biomedicines, Vol 11, Iss 6, p 1747 (2023)
Upregulation of cyclooxygenase (COX-2) plays an important role in lung cancer pathogenesis. Celecoxib (CLX), a selective COX-2 inhibitor, may have beneficial effects in COVID-19-induced inflammatory storms. The current study aimed to develop carrier-
Externí odkaz:
https://doaj.org/article/303329ebfdfb41afaad7abc99fbf03ba
Autor:
Jalil Rashedi, Amir Ghorbani Haghjo, Mehran Mesgari Abbasi, Ali Dastranj Tabrizi, Shadi Yaqoubi, Davoud Sanajou, Zahra Ashrafi Jigheh, Ali Namvaran, Ali Mohammadi, Jalal Mohammadi Khoshraj, Behzad Baradaran
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 9, Iss 3, Pp 409-415 (2019)
Purpose: This study was aimed to evaluate the site-specific drug delivery of 5-FU with chitosan (CS) as a carrier and quercetin (Qu) against induced colon cancer in Wistar rats. Methods: Cross-linked CS-Qu nanoparticles (NPs) were prepared by ionotro
Externí odkaz:
https://doaj.org/article/f2d87da2c5be413784a52dc929862e2f
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 895 (2022)
It has been hypothesized that simvastatin could be used to treat pulmonary arterial hypertension (PAH). This study is intended to formulate a simvastatin nanoparticle dry powder inhalation (DPI) formulation. Simvastatin nanoparticles were prepared vi
Externí odkaz:
https://doaj.org/article/04283cf57ad04439abfa5505ba7d75ea
Publikováno v:
Pharmaceutical Sciences, Vol 22, Iss 1, Pp 22-27 (2016)
Background: The objective of the present study was to investigate the combinative effect of ball milling and solvent displacement method on size reduction of Celecoxib particles. Celecoxib is a poorly water soluble cyclooxygenase 2 inhibitor which ha
Externí odkaz:
https://doaj.org/article/73dbef69ec774b6cbc22b484cf7bc34e
Autor:
Hamishehkar, Azin Jahangiri, Ali Nokhodchi, Kofi Asare-Addo, Erfan Salehzadeh, Shahram Emami, Shadi Yaqoubi, Hamed
Publikováno v:
Biomedicines; Volume 11; Issue 6; Pages: 1747
Upregulation of cyclooxygenase (COX-2) plays an important role in lung cancer pathogenesis. Celecoxib (CLX), a selective COX-2 inhibitor, may have beneficial effects in COVID-19-induced inflammatory storms. The current study aimed to develop carrier-
Autor:
Omid Jamshidi Kandjani, Shadi Yaqoubi, Samad Shams Vahdati, Behnam Borhannejad, Siavoush Dastmalchi, Ali Akbar Alizadeh
Publikováno v:
European Journal of Medicinal Chemistry. 250:115182
Publikováno v:
Journal of Drug Delivery Science and Technology. 78:103958